ANDA 215522, held by Taro. Sildenafil Citrate.
As of Nov 15, 2026, ANDA 215522 (Sildenafil Citrate), held by Taro, was first approved by FDA on Nov 16, 2021, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 16, 2021 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Sildenafil CitrateEQ 10MG BASE/ML ยท for suspension;oral | Sildenafil Citrate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
